TCM
CNTA

TCG Crossover Management’s Centessa Pharmaceuticals CNTA Stock Holding History

TCG Crossover Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$170M Hold
4,286,480
– – 4.87% 5
2025
Q4 		$107M Buy
4,286,480
+1,150,000
+37% +$29.1M 3.55% 5
2025
Q3 		$76.1M Buy
3,136,480
+245,664
+8% +$4.37M 3.74% 5
2025
Q2 		$38M Hold
2,890,816
– – 4.34% 8
2025
Q1 		$41.6M Hold
2,890,816
– – 5.67% 3
2024
Q4 		$48.4M Hold
2,890,816
– – 4.73% 5
2024
Q3 		$46.2M Hold
2,890,816
– – 3.92% 13
2024
Q2 		$26.1M Buy
2,890,816
+850,000
+42% +$8.06M 2.72% 15
2024
Q1 		$23.1M Hold
2,040,816
– – 1.82% 23
2023
Q4 		$16.2M Hold
2,040,816
– – 1.8% 20
2023
Q3 		$13.2M Buy
+2,040,816
New +$14M 1.94% 19

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCG Crossover Management's CNTA Position: Q1 2026 in Review

TCG Crossover Management held its Centessa Pharmaceuticals (CNTA) position steady in Q1 2026 at 4,286,480 shares worth $170M. The position accounts for 4.87% of the portfolio, ranked #5.

TCG Crossover Management first reported a position in CNTA in Q3 2023 and has held it in 11 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • TCG Crossover Management held 4,286,480 shares of Centessa Pharmaceuticals worth $170M as of Q1 2026.
  • TCG Crossover Management left its Centessa Pharmaceuticals share count unchanged in Q1 2026.
  • Centessa Pharmaceuticals made up 4.87% of TCG Crossover Management's portfolio in Q1 2026, its #5 holding.
  • TCG Crossover Management first reported a position in Centessa Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.